Market Cap (In CHF)
216.39 Million
Revenue (In CHF)
152.38 Million
Net Income (In CHF)
-297.92 Million
Avg. Volume
984.09 Thousand
- Currency
- CHF
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.6115-3.7
- PE
- -0.58
- EPS
- -1.65
- Beta Value
- 1.286
- ISIN
- CH0363463438
- CUSIP
- H3879B109
- CIK
- -
- Shares
- 224238500.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jean-Paul Clozel M.D.
- Employee Count
- -
- Website
- https://www.idorsia.com
- Ipo Date
- 2017-06-16
- Details
- Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
More Stocks
-
AL-PAAir Lease Corporation
AL-PA
-
BOVNF
-
AV-BAviva PLC
AV-B
-
SHILPAMEDShilpa Medicare Limited
SHILPAMED
-
CHT
-
138490Kolon Plastics, Inc.
138490
-
TABREED
-
9511